These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38574200)

  • 21. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine-dependent compensation maintains motor behavior in mice with developmental ablation of dopaminergic neurons.
    Golden JP; Demaro JA; Knoten A; Hoshi M; Pehek E; Johnson EM; Gereau RW; Jain S
    J Neurosci; 2013 Oct; 33(43):17095-107. PubMed ID: 24155314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias.
    Colloby SJ; McParland S; O'Brien JT; Attems J
    Brain; 2012 Sep; 135(Pt 9):2798-808. PubMed ID: 22961551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
    Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
    Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
    Duda J; Pötschke C; Liss B
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioral and neurotransmitter abnormalities in mice deficient for Parkin, DJ-1 and superoxide dismutase.
    Hennis MR; Seamans KW; Marvin MA; Casey BH; Goldberg MS
    PLoS One; 2013; 8(12):e84894. PubMed ID: 24386432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.
    Pinto M; Nissanka N; Peralta S; Brambilla R; Diaz F; Moraes CT
    Mol Neurodegener; 2016 Apr; 11():25. PubMed ID: 27038906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
    Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
    Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress.
    Pickrell AM; Huang CH; Kennedy SR; Ordureau A; Sideris DP; Hoekstra JG; Harper JW; Youle RJ
    Neuron; 2015 Jul; 87(2):371-81. PubMed ID: 26182419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Admixing of MPTP-Resistant and Susceptible Mice Strains Augments Nigrostriatal Neuronal Correlates to Resist MPTP-Induced Neurodegeneration.
    Vidyadhara DJ; Yarreiphang H; Raju TR; Alladi PA
    Mol Neurobiol; 2017 Oct; 54(8):6148-6162. PubMed ID: 27704331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
    Bezard E; Jaber M; Gonon F; Boireau A; Bloch B; Gross CE
    Eur J Neurosci; 2000 Aug; 12(8):2892-900. PubMed ID: 10971632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenosine A
    Nunes ACL; Carmo M; Behrenswerth A; Canas PM; Agostinho P; Cunha RA
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease.
    Struzyna LA; Browne KD; Brodnik ZD; Burrell JC; Harris JP; Chen HI; Wolf JA; Panzer KV; Lim J; Duda JE; España RA; Cullen DK
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1702-1716. PubMed ID: 29766664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors.
    Andersson DR; Björnsson E; Bergquist F; Nissbrandt H
    Exp Neurol; 2010 Jan; 221(1):251-9. PubMed ID: 19944096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late-onset Parkinsonism in NFκB/c-Rel-deficient mice.
    Baiguera C; Alghisi M; Pinna A; Bellucci A; De Luca MA; Frau L; Morelli M; Ingrassia R; Benarese M; Porrini V; Pellitteri M; Bertini G; Fabene PF; Sigala S; Spillantini MG; Liou HC; Spano PF; Pizzi M
    Brain; 2012 Sep; 135(Pt 9):2750-65. PubMed ID: 22915735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pitx3 deficiency produces decreased dopamine signaling and induces motor deficits in Pitx3(-/-) mice.
    Le W; Zhang L; Xie W; Li S; Dani JA
    Neurobiol Aging; 2015 Dec; 36(12):3314-3320. PubMed ID: 26363812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease.
    Colebrooke RE; Humby T; Lynch PJ; McGowan DP; Xia J; Emson PC
    Eur J Neurosci; 2006 Nov; 24(9):2622-30. PubMed ID: 17100850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycine transporter-1 inhibition promotes striatal axon sprouting via NMDA receptors in dopamine neurons.
    Schmitz Y; Castagna C; Mrejeru A; Lizardi-Ortiz JE; Klein Z; Lindsley CW; Sulzer D
    J Neurosci; 2013 Oct; 33(42):16778-89. PubMed ID: 24133278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.